The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Open accessAbstract
Immune checkpoint blockade of the inhibitory immune receptors PD-L1, PD-1 and CTLA-4 has emerged as a successful treatment strategy for several advanced cancers. Here we demonstrate that miR-424(322) regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer. miR-424(322) is inversely correlated with PD-L1, PD-1, CD80 and CTLA-4 expression. High levels of miR-424(322) in the tumours are positively correlated with the progression-free survival of ovarian cancer patients. Mechanistic investigations demonstrated that miR-424(322) inhibited PD-L1 and CD80 expression through direct binding to the 3′-untranslated region. Restoration of miR-424(322) expression reverses chemoresistance, which is accompanied by blockage of the PD-L1 immune checkpoint. The synergistic effect of chemotherapy and immunotherapy is associated with the proliferation of functional cytotoxic CD8+ T cells and the inhibition of myeloid-derived suppressive cells and regulatory T cells. Collectively, our data suggest a biological and functional interaction between PD-L1 and chemoresistance through the microRNA regulatory cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationChen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Self-citationLindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
microRNAs: a newly described class of encoded molecules that play a role in health and disease.
Felekkis, K. N., Touvana, E., Stefanou, C., & Deltas, C. C. (2010) · PubMed · Cited by 378
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Armstrong, D. K. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_5-20 · Cited by 303
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Odunsi, K. O., Jungbluth, A. A., Stockert, E., Qian, F., Gnjatic, S., Tammela, J., Intengan, M., Beck, A. F., Keitz, B. T., Santiago, D., et al. (2003) · PubMed · Cited by 249
Self-citationAbiko, K., Mandai, M., Hamanishi, J., Yoshioka, Y., Matsumura, N., Baba, T., Yamaguchi, K., Murakami, R., Yamamoto, A., Kharma, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2199 · Cited by 221
Gong, A.-Y., Zhou, R., Hu, G., Li, X., Splinter, P. L., O'Hara, S. P., LaRusso, N. F., Soukup, G. A., Dong, H., & Chen, X.-M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1325 · Cited by 217
Wang, C. J., Heuts, F., Ovcinnikovs, V., Wardzinski, L., Bowers, C., Schmidt, E. M., Kogimtzis, A., Kenefeck, R., Sansom, D. M., & Walker, L. S. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414576112 · Cited by 179
Self-citationLu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 177
Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Self-citationThe Environment of Regulatory T Cell Biology: Cytokines, Metabolites, and the Microbiome
Hoeppli, R. E., Wu, D., Cook, L., & Levings, M. K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00061 · Cited by 162
The Role of MicroRNAs in Regulatory T Cells and in the Immune Response
Ha, T. (2011) · Immune Network · doi:10.4110/in.2011.11.1.11 · Cited by 152
Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells
Cai, Q., Yan, L., & Xu, Y. (2014) · Oncogene · doi:10.1038/onc.2014.264 · Cited by 134
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 133
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
Postow, M. A., & Momtaz, P. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53163 · Cited by 114
Ghanekar, S., Nomura, L. E., Suni, M. A., Picker, L. J., Maecker, H. T., & Maino, V. C. (2001) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.3.628-631.2001 · Cited by 88
Cryptosporidium parvumInduces B7‐H1 Expression in Cholangiocytes by Down‐Regulating MicroRNA‐513
Gong, A., Zhou, R., Hu, G., Liu, J., Sosnowska, D., Drescher, K. M., Dong, H., & Chen, X. (2009) · The Journal of Infectious Diseases · doi:10.1086/648589 · Cited by 82
Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates
Kelnar, K., Peltier, H. J., Leatherbury, N., Stoudemire, J., & Bader, A. G. (2014) · Analytical Chemistry · doi:10.1021/ac403044t · Cited by 70
Abad, C., Nobuta, H., Li, J., Kasai, A., Yong, W. H., & Waschek, J. A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012531 · Cited by 60
Arias, D. A. A., Kim, H. J., Zhou, P., Holderried, T. A. W., Wang, X., Dranoff, G., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0121 · Cited by 54
The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer
Wang, T., Liu, Z., Guo, S., Wu, L., Li, M., Yang, J., Chen, R., Xu, H., Cai, S., Chen, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1968 · Cited by 43
Self-citationWang, T., Song, W., Chen, Y., Chen, R., Liu, Z., Wu, L., Li, M., Yang, J., Wang, L., Liu, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1632 · Cited by 31
Self-citationMIRNAS as Prognostic and Therapeutic Tools in Epithelial Ovarian Cancer
Nagaraj, A. B., Joseph, P. L., & DiFeo, A. V. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.108 · Cited by 26
Cited by
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X., & Zhu, J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0719-3 · Cited by 517
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Metadata
- Authors
- Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y., Wang, T., Song, W., Chen, Y., OuYang, J., Chen, J., Kong, F., Dong, Y., Jiang, S.-W., Li, W., Wang, P., Yuan, Z., Wan, X., Wang, C., Li, W., Zhang, X., & Chen, K.
- Venue
- Nature Communications
- Published
- 2016-05-05
- Volume
- 7
- Issue
- 1
- Pages
- 11406-11406
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2345664901
- Cited by
- 287
- References
- 38
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.